AVE 33.3% 0.2¢ avecho biotechnology limited

success! , page-38

  1. 1,913 Posts.
    This is from PHOSPHAGENICS US-based commercialiazation partner Neura Therapeutik.

    PAIN costs the US $635billion annually

    Industry analysts estimate that more than 1.5 billion people around the world suffer from chronic pain, making it the number one reason patients seek medical care. In fact, studies have shown that pain leads to more than 50 million lost workdays each year. The cost of pain, including medical bills and lost workdays, is estimated at $100 billion per year. The US market for pain-management therapeutics is estimated to generate more than $40 billion annually and is predicted to grow to $60 billion by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer pain, arthritis pain, migraine pain, neuropathic pain, and back pain.
    Imagine the global market because make no doubt this will be a global product.

    Make up for my loss from POH at the start of the year.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.2¢
Change
-0.001(33.3%)
Mkt cap ! $6.338M
Open High Low Value Volume
0.3¢ 0.3¢ 0.2¢ $11.50K 4.335M

Buyers (Bids)

No. Vol. Price($)
63 101422109 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 20872825 7
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.